Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on ...

Chardan notes that Allurion has announced additional data evaluating the use of its Allurion Balloon in combination with patients be treated ...

Seven months after suspending sales of its weight loss balloon in France due to safety concerns, Allurion’s products are back on sale in the country. In August 2024, the US company agreed to ...

Roth MKM keeps a Buy rating and $16 price target on Allurion Technologies (ALUR) after its initial results from Allurion Program-GLP-1 combo.

Allurion Technologies (NYSE:ALUR – Get Free Report) is anticipated to release its earnings data before the market opens on ...

The study will focus on combination use of the Allurion Balloon with lower dose GLP-1s with the goal of demonstrating improved long-term tolerability and adherence to GLP-1 therapy. Previous ...

52 patients treated with the Allurion Balloon were started on 0.25mg semaglutide after completing their first month of balloon therapy. The dose of semaglutide was increased to no greater than 1 ...

Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the ...

These patents, both of which are scheduled to issue on March 11, 2025, provide additional claims for an enhanced, next-generation version of Allurion’s proprietary Balloon technology for the ...

Forman, and Allurion Technologies are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small cap stocks represent shares of smaller companies, typically with ...

Microcap Allurion Technologies (NYSE:ALUR) surged ~31% in after-hours trading Thursday after posting preliminary data on weight loss associated with its gastric balloon in combination with Novo ...